Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates

Reported new Phase 1b/2 data from lead KRAS-mutated metastatic colorectal cancer (mCRC) clinical program showing objective response rate and median...

Related Keywords

United States ,American ,Heinz Josef Lenz ,Acta Oncologica ,Mark Erlander ,Amy Jobe ,Joyce Allaire ,James Levine ,Cardiff Oncology Inc ,Crc Program ,Prnewswire Cardiff Oncology Inc ,Nasdaq ,Exchange Commission ,Crpc Program ,American Association For Cancer Research ,Lifesci Communications ,Norris Comprehensive Cancer Center ,Cardiff Oncology ,Comprehensive Cancer Center ,American Society ,Castration Resistant Prostate Cancer ,American Association ,Cancer Research ,Annual Meeting ,Months Ended March ,Lancet Oncol ,Correspondence Lancet Oncol June ,Private Securities Litigation Reform Act ,Oncology Contact ,Nc ,